Hematology

Resource Center

News
Research Summaries
Resources
FDA Alerts Pearls of Wisdom From the Journal
Insights
Podcasts Q&As
Interactive
Polls Quizzes
Events & Education
ASH Annual Meeting

Featured

Timelines
Notable FDA Approvals
Timelines
Notable FDA Approvals in July
07/23/2026
July 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...
07/23/2026
FDA Approval
doctor writing on chart
FDA Approval
FDA Approves Subcutaneous Isatuximab-irfc for Multiple Myeloma Indications
07/23/2026
Anthony Calabro, MA
The FDA approved subcutaneous isatuximab-irfc (Sarclisa Escena, Sanofi-Aventis US LLC) for multiple myeloma treatment regimens across relapsed, refractory, and newly diagnosed disease settings.
07/23/2026
FDA Approval
FDA logo
FDA Approval
FDA Expands Casgevy Approval to Children Aged 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent β-Thalassemia
07/21/2026
Anthony Calabro, MA
The FDA expanded approval of exagamglogene autotemcel (Casgevy) for patients aged 2 years and older with sickle cell disease and recurrent vaso-occlusive crises or transfusion-dependent β-thalassemia. ...
07/21/2026

Interactive Features

Photoclinic Challenge
Infant with a 5 × 5 × 2 cm, well-circumscribed, violaceous lesion on the right posterior thigh
Photoclinic Challenge
Fully Formed at Birth: A Neonatal Vascular Lesion Challenge Case Description
03/28/2026
Ashton L. Stahl
A full-term newborn presents with a fully formed, violaceous vascular lesion at birth. With imaging revealing mixed vascular flow and no postnatal proliferation, can you distinguish this rare entity from...
03/28/2026
Pop Quiz
Pop Quiz
Pop Quiz
Understanding Richter Transformation in Chronic Lymphocytic Leukemia
10/14/2025
Miranda Manier, BA
Richter transformation of chronic lymphocytic leukemia carries poor outcomes with traditional therapies, but emerging treatments may improve survival. Test your knowledge of prognosis by taking this quick...
10/14/2025
Pop Quiz
Myelofibrosis
Pop Quiz
Which JAK Inhibitor Remains the Standard of Care in Myelofibrosis?
09/25/2025
Miranda Manier, BA
In an interview with Consultant360, Junaid Anwar, MD, a hematology-oncology fellow at UT Health Houston, reviewed the current evidence base for JAK inhibitors in myelofibrosis from a pooled analysis of five...
09/25/2025
Pop Quiz
pop quiz
Pop Quiz
A Serious Complication of Chronic Lymphocytic Leukemia
08/13/2025
Anthony Calabro, MA
The survival outcomes for patients diagnosed with this chronic lymphocytic leukemia complication have remained poor for decades. Can you name the complication? Take the quiz to find out!
08/13/2025
3-in-30
Blood cells
3-in-30
Silent but Common: Quick Questions on Iron Deficiency in Adults
06/26/2025
Miranda Manier, BA
Iron deficiency often goes unnoticed until symptoms interfere with daily life—or worse. Can you catch the clinical clues in time?
06/26/2025

Clinical Insights

Sponsored Video
Tim F and Dr Haddad
Sponsored Video
Myelofibrosis Caregiver Interview Series: Caregiver Input for Myelofibrosis Treatment Plans
06/08/2026
Fadi G. Haddad, MD
In the final installment of the Myelofibrosis Caregiver Interview Series, Fadi Haddad, MD interviews Tim F., a caregiver from Pittsburgh, PA, about the critical role caregivers play in shared...
06/08/2026
Sponsored
Tim F.
Sponsored
Myelofibrosis Caregiver Interview Series: The Impact of Myelofibrosis on Caregivers
05/18/2026
Fadi G. Haddad, MD
In the latest installment of the Myelofibrosis Caregiver Interview Series, Tim F. from Pittsburgh, PA, talks with Fadi Haddad, MD about the caregiver perspective, highlighting the substantial day-to-day...
05/18/2026
Sponsored
Fadi Haddad, MD
Sponsored
Myelofibrosis Caregiver Interview Series: Involving Patients and Caregivers in Myelofibrosis Treatment Plans
05/06/2026
Fadi G. Haddad, MD
In the next installment of the Myelofibrosis Caregiver Interview Series, Fadi Haddad, MD, emphasizes a patient- and caregiver-centered approach to treatment planning—highlighting how clinical decisions...
05/06/2026
Sponsored
Tim F. and Fadi Haddad, MD
Sponsored
Myelofibrosis Caregiver Interview Series: Monitoring Myelofibrosis Treatment Effectiveness
04/21/2026
Fadi G. Haddad, MD
Monitoring treatment response in myelofibrosis requires a balanced assessment of patient-reported symptoms, objective scoring tools, hematologic parameters, and spleen size. In part 1 of this Myelofibrosis...
04/21/2026
Expert Q&A
Brady L Stein, MD
Expert Q&A
How the ASH Clinical Practice Guidelines Aim to Improve Myelofibrosis Management
12/22/2025
Brady L. Stein, MD
At the 2025 American Society of Hematology (ASH) Annual Meeting, Brady Stein, MD, chaired a session introducing the forthcoming ASH Clinical Practice Guidelines on Myelofibrosis—the first ASH-supported...
12/22/2025